2019 GU Cancers Symposium: First-Line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma
As reported at the 2019 Genitourinary Cancers Symposium and in The New England Journal of Medicine, Rini et al found significant benefits in overall and progression-free survival with the combination...
2019 GU Cancers Symposium: TIVO-3: Tivozanib vs Sorafenib in Refractory Advanced Renal Cell Carcinoma
The TIVO-3 trial was conducted to confirm progression-free survival results from the TIVO-1 trial, which found an improvement...
Benefit of Annual Screening in Women Aged 35–39 With a Family History of Breast Cancer
Annual screening for women aged 35–39 who have a family history of breast cancer may be highly effective in detecting tumors earlier...
DYNAMO: Duvelisib in Refractory Indolent Non-Hodgkin Lymphoma
In the phase II DYNAMO trial reported in the Journal of Clinical Oncology, Flinn et al found a response rate of nearly 50% with duvelisib, an oral dual inhibitor...
Progress With ALK Inhibitors: When Will We Consider ALK-Positive Lung Cancer a ‘Chronic Disease’?
As reported by Solomon et al in The Lancet Oncology and reviewed in this issue of The ASCO Post, results from a global phase II study of the third-generation ALK inhibitor lorlatinib...
Allen Lichter: The Potential of Value-Based Prescribing in Oncology
Karen Reckamp: PACIFIC Trial of Durvalumab in Stage III Unresectable NSCLC
Damien Hansra: Breast Cancer Surgical Terminology Update
Thomas Witzig: Essential Elements of an Effective Clinical Trials System
Fred Hirsch: Progress With ALK Inhibitors
More Top Stories
Role of Adjuvant Capecitabine in Triple-Negative Breast Cancer
ADJUVANT CAPECITABINE added to standard neoadjuvant chemotherapy failed to significantly improve disease-free or overall survival in patients with early triple-negative breast cancer in the large phase III CIBOMA/2004-01_GEICAM/2003-11 (CIBOMA/GEICAM) trial.1 However, extended treatment with...
2019 GU Cancers Symposium: First-Line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma
As reported at the 2019 Genitourinary Cancers Symposium (Abstract 543) and in The New England Journal of Medicine, Rini et al found significant benefits in overall and progression-free survival with the combination of pembrolizumab plus axitinib vs sunitinib in the first-line treatment of advanced...
Taking a Stand: How ASCO Develops Policy Guidance and Position Statements
As a global thought leader in the spheres of cancer care and research, ASCO recognizes the importance of taking a position on certain key issues affecting its members and the patients they serve. As a result, ASCO will, on occasion, release policy guidance and position statements when existing...
FDA Approves Ibrutinib in Combination With Obinutuzumab in Treatment-Naive CLL/SLL
ON JANUARY 28, 2019, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica), a Bruton’s tyrosine kinase inhibitor, in combination with obinutuzumab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is the first approval of ...
Benefit of Annual Screening in Women Aged 35–39 With a Family History of Breast Cancer
Annual screening for women aged 35–39 who have a family history of breast cancer may be highly effective in detecting tumors earlier, according to findings published by Evans et al in The Lancet’s online journal EClinicalMedicine. The FH02 trial found that annual mammograms for...
Primary Prophylaxis With a Direct Oral Anticoagulation Agent Reduces Venous Thromboembolism Rate in Ambulatory Patients With Cancer
LATE-BREAKING results from the large, randomized, placebo-controlled CASSINI trial showed that primary prophylaxis with the direct oral anticoagulation agent rivaroxaban reduced the incidence of venous thromboembolism (VTE) as well as VTE-related deaths in high-risk patients with cancer who were...
Cutaneous T-Cell Lymphoma: Can Genetic Polymorphisms Help Select Patients for Treatment With Bexarotene?
Bexarotene is a retinoid approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have not responded to at least one previous treatment regimen. Hypertrigylceridemia is the most frequent adverse event related to treatment with bexarotene in CTCL. Even with prophylactic...
Facing Death: Having the Difficult Conversation With Your Patients
Zaida Morante, MD, on Triple-Negative Breast Cancer: Delaying Adjuvant Chemotherapy
Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents
Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Results From the NIVOREN GETUG-AFU 26 Study on Nivolumab
